When Allison Shapiro, a physician-scientist at the University of Colorado, pulled up the brain scans of 13 young women taking a GLP-1 medication for a hormonal disorder, she expected to see very little. The drug was treating their ovaries. Their brains were supposed to be unchanged.

They weren't.

The scans showed something she hadn't planned for — increased activity and connectivity inside a brain network called the salience network, the system that decides what deserves your attention and what doesn't. "We didn't expect to see this effect, and we really don't know what it means," she said.

That sentence — honest, open, a little unsettling — captures exactly where GLP-1 science stands right now.

What is a GLP-1 drug, and how does it work?

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally releases after a meal. It tells your pancreas to produce insulin, slows how quickly food leaves your stomach, and signals your brain: you're full, you can stop eating.1

Medications like Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound are engineered versions of this hormone. They mimic the natural signal but last far longer in the body — which is why they produce sustained effects on appetite and blood sugar.

For years, doctors understood this as a gut story. The drug slows stomach emptying. It reduces appetite. Patients eat less. They lose weight. Simple enough.

Except it isn't.

The brain was never supposed to be part of this

As millions of people began taking GLP-1 drugs, something unexpected kept appearing in patient reports. People weren't just losing interest in food. They were losing interest in alcohol. In cigarettes. In compulsive shopping. In behaviors that had nothing to do with their stomach.

Researchers began asking a different question: What if these drugs aren't just working in the gut — what if they're working in the brain?

The answer, increasingly, appears to be yes. Scientists have now found GLP-1 receptors throughout the brain — in regions tied to reward, emotion, memory, and impulse control. These aren't accidental locations. They suggest the brain was always part of this story. We just weren't looking for it.2

The drug quiets the part of your brain that screams I want that — and the effect isn't limited to food.

What the science shows

A 2026 NIH-funded study found that oral GLP-1 drugs penetrate deep into the brain, reaching areas that injected versions cannot. Specifically, they activate the central amygdala — the brain's emotional alarm center — and appear to reduce dopamine release into reward circuits during pleasure-driven eating.

In plain English: the drug quiets the part of your brain that screams I want that when you see something rewarding. This is why patients on Ozempic often describe their relationship with food differently. They don't hate pizza — they just stop thinking about it. The craving loses its grip.

Because the reward circuits affected by GLP-1s aren't food-specific — they're the same circuits involved in alcohol use, gambling, compulsive habits, and other driven behaviors — the drug appears to blunt those drives too.3

Clinical note

As a vascular neurologist, I find this particularly relevant to our patient population. The same dopaminergic reward pathways being modulated by GLP-1 drugs are implicated in post-stroke behavioral changes, depression, and apathy. Whether GLP-1 drugs could eventually have a role in post-stroke recovery is an open and genuinely interesting question — one worth watching. For context on how brain recovery and neuroplasticity work after stroke, see our article on early stroke rehabilitation.

The effect nobody planned for

Here is where the story gets more complicated. Some patients taking GLP-1 drugs report something beyond reduced cravings. They describe a kind of emotional quieting — less motivation, less desire, less excitement about things they used to love. Hobbies feel flat. Relationships feel distant. Life, some say, feels a little gray.

This raises a difficult question that scientists and ethicists are only beginning to wrestle with: If a drug reshapes the brain circuits tied to desire and reward, how do you know when it has helped you — and when it has changed you?

There is no clean answer yet.

Could this help with more than weight?

On the other side of the coin, researchers are finding signals that may be genuinely important for neurological medicine:

  • Addiction medicine. GLP-1 drugs appear to reduce cravings for alcohol and nicotine in some patients, independent of any weight loss effect — a finding now being pursued in dedicated clinical trials.3
  • Brain inflammation. Some researchers believe GLP-1s calm overactive brain immune cells called microglia, reducing chronic neuroinflammation linked to cognitive decline — a mechanism with direct relevance to vascular dementia and post-stroke cognitive impairment. Our article on stroke and dementia explores this relationship in detail.
  • Alzheimer's disease. Early laboratory studies show GLP-1 drugs may reduce levels of beta-amyloid and tau — the two proteins that accumulate in Alzheimer's brains. Human clinical trials are underway.5

None of this is proven at scale yet. But the direction of evidence is striking.

The largest unplanned neuroscience experiment in history

Daniel Drucker, one of the scientists involved in early GLP-1 research at the University of Toronto, described a pattern he kept hearing from physicians: patients whose blood sugar they were treating would come back to the office saying they felt noticeably happier. Not just lighter — better.1

Whether that reflects the drug's neurological effects, the psychological relief of improved health, or something else entirely is not yet known. What is known is this: more than 50 million people are now taking GLP-1 drugs worldwide. Most signed up for a weight loss medication. Many may be experiencing neurological effects that no one fully understands yet. That is, as one researcher described it, the largest unplanned neuroscience experiment in the history of modern medicine.

What this means for patients

The science does not say you should stop taking a GLP-1 medication. The metabolic and weight loss benefits are well-established and significant for many people. What it does say is this:

  • Changes in mood, motivation, or emotional affect while on a GLP-1 drug are worth discussing with your physician — they may be real, drug-related effects, not imaginary.
  • Reduced cravings for alcohol or compulsive habits have been widely reported and are being actively studied — tell your doctor if you notice this.
  • Long-term neurological effects, especially in younger patients whose brains are still developing, remain unknown. More research is coming.

The gut story was always more complicated than it appeared. Scientists are just now beginning to understand how much more.